全文获取类型
收费全文 | 5366篇 |
免费 | 397篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 199篇 |
妇产科学 | 138篇 |
基础医学 | 825篇 |
口腔科学 | 134篇 |
临床医学 | 438篇 |
内科学 | 1269篇 |
皮肤病学 | 252篇 |
神经病学 | 576篇 |
特种医学 | 59篇 |
外科学 | 463篇 |
综合类 | 27篇 |
预防医学 | 454篇 |
眼科学 | 146篇 |
药学 | 398篇 |
中国医学 | 33篇 |
肿瘤学 | 353篇 |
出版年
2023年 | 43篇 |
2022年 | 98篇 |
2021年 | 188篇 |
2020年 | 107篇 |
2019年 | 170篇 |
2018年 | 190篇 |
2017年 | 136篇 |
2016年 | 154篇 |
2015年 | 166篇 |
2014年 | 229篇 |
2013年 | 281篇 |
2012年 | 469篇 |
2011年 | 474篇 |
2010年 | 266篇 |
2009年 | 205篇 |
2008年 | 360篇 |
2007年 | 320篇 |
2006年 | 300篇 |
2005年 | 325篇 |
2004年 | 281篇 |
2003年 | 242篇 |
2002年 | 265篇 |
2001年 | 34篇 |
2000年 | 38篇 |
1999年 | 41篇 |
1998年 | 32篇 |
1997年 | 37篇 |
1996年 | 37篇 |
1995年 | 25篇 |
1994年 | 14篇 |
1993年 | 12篇 |
1992年 | 20篇 |
1991年 | 14篇 |
1990年 | 13篇 |
1989年 | 14篇 |
1988年 | 19篇 |
1987年 | 11篇 |
1986年 | 15篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1981年 | 10篇 |
1978年 | 6篇 |
1974年 | 7篇 |
1973年 | 7篇 |
1972年 | 10篇 |
1971年 | 6篇 |
1970年 | 7篇 |
1969年 | 8篇 |
1966年 | 9篇 |
1965年 | 5篇 |
排序方式: 共有5785条查询结果,搜索用时 31 毫秒
61.
62.
63.
A. Wiecek M. Nowicki D. Fliser E. Ritz 《European journal of clinical pharmacology》1995,48(3-4):203-208
Moxonidine and related compounds have been recently introduced into antihypertensive therapy. It is thought that these drugs exert their blood pressure lowering effect through interaction with nonadrenergic receptors in the central nervous system, i.e. imidazoline receptors, although the contribution of specific interaction with 2-receptors is still under debate. Imidazoline receptors have recently been documented in the renal proximal tubule. In experimental studies, interaction of imidazolines with these receptors decreased the activity of the Na+/H+ antiporter and induced natriuresis. To quantitate the effect of the imidazoline receptor agonist moxonidine on renal sodium handling and renal haemodynamics in man, we examined ten healthy normotensive males (aged 25 ± 4 years) in a double blind placebo-controlled study using a crossover design. Subjects were studied on a standardized salt intake (50 mmol per day). On the 7th and 10th study day they were randomly allocated to receive either i.v. placebo or i.v. 0.2 mg moxonidine. Urinary electrolyte excretion, lithium clearance (as an index of proximal tubular sodium handling), glomerular filtration rate (GFR), effective renal plasma flow (ERPF), renal vascular resistance (RVR), mean arterial blood pressure (MAP), plasma renin activity (PRA) and plasma noradrenaline (NA) levels were assessed. Injection of moxonidine did not increase fractional sodium excretion or lithium clearance. Specifically, antinatriuresis was not observed after injection of moxonidine despite a significant decrease in MAP from 91 to 85 mmHg and a significant increase in PRA. MAP and PRA did not change with administration of placebo. Injection of moxonidine did not affect GFR and RVR; ERPF decreased slightly but not significantly. Acute administration of 0.2 mg i.v. moxonidine decreased blood pressure in healthy volunteers on standardized salt intake, but did not affect natriuresis, proximal tubular sodium reabsorption or glomerular filtration rate. The absence of an antinatriuretic response despite a decrease in blood pressure suggests a direct facilitation of natriuresis by moxonidine. 相似文献
64.
Heparin-binding epidermal growth factor-like growth factor protects rat intestine from ischemia/reperfusion injury 总被引:8,自引:0,他引:8
Pillai SB Hinman CE Luquette MH Nowicki PT Besner GE 《The Journal of surgical research》1999,87(2):225-231
BACKGROUND: We have shown previously that heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is cytoprotective for intestinal epithelial cells exposed to hypoxia in vitro. We now examine the effects of HB-EGF on the recovery of small intestine from ischemic injury in vivo. METHODS: Segmental intestinal ischemia of 60-min duration was produced in adult rats by occlusion of a first-order branch of the superior mesenteric artery. Recombinant HB-EGF (100 microg) was injected intraluminally into the proximal small bowel after 45 min of ischemia in experimental animals, and buffered saline was injected in control animals. Animals were sacrificed after 48 h, and the affected bowel was resected, processed, and examined microscopically, with histologic grading of the ischemic injury. Additional animals were allowed to recover for up to 1 month to evaluate mortality differences. RESULTS: Intraluminal administration of HB-EGF resulted in significantly decreased extent and severity of ischemia/reperfusion injury, with significantly decreased grade of injury in the HB-EGF-treated compared with nontreated animals (average injury grade 0.66 compared with 2.44, respectively). Moreover, the mortality rate was significantly lower in the HB-EGF-treated animals compared with nontreated animals (0% vs 25%, respectively). HB-EGF-treated animals had increased weight gain in the postischemia recovery period. CONCLUSIONS: We conclude that HB-EGF, given intraluminally, reduces both the amount and the severity of ischemia/reperfusion injury in the small bowel, reduces the mortality associated with intestinal ischemia, and may enhance intestinal recovery. The in vitro and in vivo cytoprotective effects of this growth factor suggest that it may, in the future, be clinically useful in treating patients with intestinal ischemia. 相似文献
65.
The whole work was aimed at experimental estimation of the healing process in case of carbon fibre vascular prostheses implanted into the abdominal aorta of a dog. The tests applied to carbon fibre woven prostheses made in the USSR. All metrological and chemical tests were performed at the Knitting Industry Main Centre for Research and Development "Tricomed" in Lód?. Experimental examinations were performed on 12 dogs. Prostheses were implanted into dog's abdominal aorta "end to the end" with the help of threads type Mersilen 4-0 or Prolen 4-0. The dogs were observed for 53 to 121 days, i.e. their behaviour, condition of the postoperative wound and presence of pulse in the femoral arteries were taken into consideration. Upon the completion of the observation autopsy was performed. Thus obtained material was fixed in 9% formalin and next various dyeing methods were applied to it. During examination in autopsy no inflammatory reactions in the tissues adjacent to implanted prostheses were discovered. In each case there was a continuous and firm adhesion of prosthesis and neighbouring inferior caval vein. A newly developed so called "neoadventitia" in the lumen of the prostheses constituted a solid and uniform film covering the wall of the prosthesis. Haematoma in the nearabout of the prosthesis was found in two cases only. Close to anastomosis ordinary clusters of lymphocytes and numerous fibroblasts as well as collagen fibre between prosthesis plexus were discovered. On the basis of the examinations performed a conclusion could be drawn, i.e. the process of healing was followed by regular structure of new aorta walls together with well developed flexible and springy fibre and neglidgeble immunological reactions. 相似文献
66.
Iranzu González Enrique J Andreu Angel Panizo Susana Inogés Ana Fontalba José Luis Fernández-Luna Mirella Gaboli Luis Sierrasesúmaga Salvador Martín-Algarra Javier Pardo Felipe Prósper Enrique de Alava 《Clinical cancer research》2004,10(2):751-761
PURPOSE AND EXPERIMENTAL DESIGN: The stem cell factor/KIT receptor loop may represent a novel target for molecular-based therapies of Ewing tumor. We analyzed the in vitro impact of KIT blockade by imatinib in Ewing tumor cell lines. RESULTS: KIT expression was detected in 4 of 4 Ewing tumor cell lines and in 49 of 110 patient samples (44.5%) by immunohistochemistry and/or Western blot analysis. KIT expression was stronger in Ewing tumors showing EWS-FLI1 nontype 1 fusions. Despite absence of c-kit mutations, constitutive and ligand-inducible phosphorylation of KIT was found in all tumor cell lines, indicating an active receptor. Treatment with KIT tyrosine kinase inhibitor imatinib (0.5-20 micro M) induced down-regulation of KIT phosphorylation and dose response inhibition of cell proliferation (IC(50), 12-15 micro M). However, imatinib administered alone at doses close to IC(50) for growth inhibition (10 micro M) did not induce a significant increase in apoptosis. We then analyzed if blockade of KIT loop through imatinib (10 micro M) was able to increase the antitumor in vitro effect of doxorubicin (DXR) and vincristine (VCR), drugs usually used in Ewing tumor treatment. Addition of imatinib decreased in 15-20 and 15-36% of the proliferative rate of Ewing tumor cells exposed to DXR and VCR, respectively, and increased in 15 and 30% of the apoptotic rate of Ewing tumor cells exposed to the same drugs. CONCLUSIONS: Inhibition of Ewing tumor cell proliferation by imatinib is mediated through blockade of KIT receptor signaling. Inhibition of KIT increases sensitivity of these cells to DXR and VCR. This study supports a potential role for imatinib in the treatment of Ewing tumor. 相似文献
67.
Lilia Suárez María-Belén Vidriales José García-Lara?a Guillermo Sanz María-José Moreno Antonio López Susana Barrena Rafael Martínez Mar Tormo Luis Palomera Esperanza Lavilla Ma Consuelo López-Berges María de Santiago M Encarnación Pérez de Equiza Jesús F San Miguel Alberto Orfao 《Clinical cancer research》2004,10(22):7599-7606
Myelodysplastic syndromes and acute myeloid leukemia (AML) are heterogeneous disorders in which conflicting results in apoptosis and multidrug resistance (MDR) have been reported. We have evaluated by multiparameter flow cytometry the expression of apoptosis- (APO2.7, bcl-2, and bax) and MDR-related proteins [P-glycoprotein (P-gp), multidrug resistance protein (MRP), and lung resistance protein (LRP)] specifically on bone marrow (BM) CD34+ cells, and their major CD32-/dim and CD32+ subsets, in de novo AML (n=90), high-risk myelodysplastic syndrome (n=9), and low-risk myelodysplastic syndrome (n=21) patients at diagnosis, and compared with normal BM CD34+ cells (n=6). CD34+ myeloid cells from AML and high-risk myelodysplastic syndrome patients displayed higher expression of bcl-2 (P <0.0001) and lower reactivity for APO2.7 (P=0.002) compared with low-risk myelodysplastic syndrome and normal controls. Similar results applied to the two predefined CD34+ myeloid cell subsets. No significant differences were found in the expression of P-gp, MRP, and LRP between low-risk myelodysplastic syndrome patients and normal BM, but decreased expression of MRP (P <0.03) in AML and high-risk myelodysplastic syndromes and P-gp (P=0.008) in high-risk myelodysplastic syndromes were detected. Hierarchical clustering analysis showed that low-risk myelodysplastic syndrome patients were clustered next to normal BM samples, whereas high-risk myelodysplastic syndromes were clustered together and mixed with the de novo AML patients. In summary, increased resistance to chemotherapy of CD34+ cells from both AML and high-risk myelodysplastic syndromes would be explained more appropriately in terms of an increased antiapoptotic phenotype rather than a MDR phenotype. In low-risk myelodysplastic syndromes abnormally high apoptotic rates would be restricted to the CD34- cell compartments. 相似文献
68.
Susana Puig Josep Malvehy Cèlia Badenas Anna Ruiz Dolores Jimenez Francisco Cuellar Antoni Azon Urbá Gonzàlez Teresa Castel Antoni Campoy Josep Herrero Rosa Martí Joan Brunet-Vidal Montserrat Milà 《Journal of clinical oncology》2005,23(13):3043-3051
PURPOSE: We have studied a consecutive case series of patients with multiple primary melanoma (MPM) for the involvement of the melanoma susceptibility loci CDKN2A and CDK4. PATIENTS AND METHODS: One hundred four MPM patients (81 patients with two primary melanomas, 14 with three, five with four, one with five, two with six, and one with seven) were included. RESULTS: Seven different CDKN2A germline mutations were identified in 17 patients (16.3%). In total, we identified 15 CDKN2A exon 2, one exon 1alpha missense mutation, and one exon 1beta frameshift mutation. The age of onset was significantly lower and the number of primary melanomas higher in patients with mutations. CDKN2A mutations were more frequent in patients with familial history of melanoma (35.5%) compared with patients without (8.2%), with a relative risk (RR) of 4.32 (95% CI, 1.76 to 10.64; P = .001), and in patients with more than two melanomas (39.1%) compared with patients with only two melanomas (10%) with an RR of 3.29 (95% CI, 1.7 to 6.3; P = .002). The A148T polymorphism was more frequent in patients with MPMs than in the control population (P = .05). A variant of uncertain significance, A127S, was also detected in one patient. No CDK4 mutations were identified, suggesting that it has a low impact in susceptibility to MPM. CONCLUSION: MPM patients are good candidates for CDKN2A mutational screening. These patients and some of their siblings should be included in a program of specific follow-up with total body photography and digital dermoscopy, which will result in the early detection of melanoma in this subset of high-risk patients and improve phenotypic characterization. 相似文献
69.
Susana B Bravo María E R García-Rendueles Rafael Seoane Vanesa Dosil José Cameselle-Teijeiro Luis López-Lázaro Juan Zalvide Francisco Barreiro Celia M Pombo Clara V Alvarez 《Clinical cancer research》2005,11(21):7664-7673
Undifferentiated (anaplastic) thyroid carcinoma is a highly aggressive human cancer with very poor prognosis. Although there have been a few studies of candidate treatments, the fact that it is an infrequent tumor makes it very difficult to design clinical trials. A strong association has been observed between undifferentiated thyroid carcinoma and TP53 mutations in numerous molecular genetic and expression studies. Plitidepsin (Aplidin, PharmaMar, Madrid, Spain) is a novel anticancer compound obtained from a sea tunicate. This compound has been reported to induce apoptosis independently of TP53 status. We investigated the actions of plitidepsin in human thyroid cancer cells. In initial experiments using primary cultured cells from a differentiated (papillary) carcinoma, we found that 100 nmol/L plitidepsin induced apoptosis, whereas lower doses were cytostatic. Because our aim was to study the effects of plitidepsin at clinically relevant concentrations, subsequent experiments were done with a dosage regimen reflecting plasma concentrations observed in previously reported clinical trials: 100 nmol/L for 4 hours, followed by 10 nmol/L for 20 hours (4(100)/20(10) plitidepsin). This plitidepsin dosage regimen blocked the proliferation of a primary undifferentiated/anaplastic thyroid carcinoma culture obtained in our laboratory and of a commercial cell line (8305C) obtained from an undifferentiated thyroid carcinoma; however, it did not induce apoptosis. The proportion of cells in the G(1) phase of the cell cycle was greatly increased and the proportion in the S/G(2)-M phases greatly reduced, suggesting that plitidepsin blocks G(1)-to-S transition. Levels of the cyclin D1/cyclin-dependent kinase 4/p21 complex proteins were decreased and, in line with this, the levels of unphosphorylated Rb1 increased. The decrease in cell cycle proteins correlated with hypoacetylation of histone H3. Finally, we did experiments to assess how rapidly tumor cells return to their initial pretreatment proliferative behavior after 4(100)/20(10) plitidepsin treatment. Cells from undifferentiated tumors needed more than 3 days to recover logarithmic growth, and after 7 days, cell number was still significantly lower than in control cultures. 4(100)/20(10) plitidepsin inhibited the growth in soft agar. Together, our data show that plitidepsin is able to block in vitro cell cycle progression at concentrations similar to serum concentrations observed in vivo, and that this effect is persistent for several days after plitidepsin removal. Whether plitidepsin will prove to be clinically useful in the treatment of undifferentiated thyroid cancers remains to be established. However, our results raise the possibility that plitidepsin might be effective alone or in combination with radiotherapy and/or other drug treatments. 相似文献
70.
Amparo Rodríguez Sánchez María J. Chueca Guindulain María Alija Merillas Susana Ares Segura José Carlos Moreno Navarro María Dolores Rodríguez Arnao 《Anales de pediatría (Barcelona, Spain : 2003)》2019,90(4):250.e1-250.e8
The screening program of congenital hypothyroidism (CH) is probably one of the best achievements in paediatrics. Thyroid hormones are essential for brain development and brain maturation that continue through the neonatal period. Hypothyroidism that begins in the first months of life causes irreversible damage to the central nervous system, and is one of the most frequent and preventable causes of mental retardation. As children with congenital hypothyroidism are born with a normal appearance, analytical studies are required to immediately start the appropriate therapy.This article analyses the aims, diagnostic procedures, tests required, aetiology, and differential diagnosis in this disorder. Especially relevant is to perform frequent monitoring to ensure dose adjustments of L-Thyroxine therapy, avoiding infra- or supra-dosing that negatively affects neurosensory functions. Re-evaluation of the aetiology permanent vs transient hypothyroidism is always recommended after 3 years of chronological age.The relevance of this screening program should be widely discussed in paediatrics. The main objective is to avoid cerebral damage in these patients, and has been highly successful and economically beneficial.Other aspects are required to optimise patient outcomes, to perform all the controls according to the recommendations and to include, in the near future, the diagnosis of central hypothyroidism. Implementation of this program is necessary to progress in accordance with current scientific knowledge. 相似文献